Categories Finance

The Capital Spectator: Investing, Asset Allocation, and Economic Insights

In recent headlines:

  • The US government has reached its debt ceiling and has initiated “extraordinary measures” to meet its financial obligations.
  • NATO gathers to discuss military support for Ukraine, facing some internal disagreements regarding the shipment of tanks.
  • The global economic outlook shows improvement, but the IMF chief warns it may not yet be a sign of recovery.
  • Major oil companies are entering the electric vehicle charging sector aggressively.
  • Google plans to eliminate approximately 12,000 jobs, around 6% of its workforce.
  • Inflation in Japan has hit a 41-year high.
  • US jobless claims decreased to 190,000, marking the lowest number in 15 weeks.
  • The Philly Fed Manufacturing Index indicates a slower pace of contraction in January.
  • Housing starts and building permits in the US continue to decline as of December.

Continue reading

Despite economists predicting a decline, the 1.1% drop in retail spending for December was sharper than anticipated. This marks the second consecutive month of declines and raises concerns. While it might be attributed to seasonal variations, in current circumstances, it serves as a cautionary signal about the potential risks to the business cycle.

Continue reading

Highlights from today:

  • The US Treasury initiates extraordinary measures for managing financial obligations.
  • US producer price inflation slowed in December.
  • Job reductions in the tech sector are increasing as Microsoft announces plans to cut 10,000 positions.
  • Federal Reserve Chairman Jerome Powell has tested positive for COVID-19.
  • The cryptocurrency firm Genesis Global Capital is preparing for bankruptcy.
  • Global bond sales have surged to an unprecedented start in 2023, nearing $600 billion.
  • US industrial output declined more than expected in December.
  • According to the Fed’s Beige Book, inflation is showing signs of slowing while the job market stays tight.
  • Home builder sentiment has increased in January, marking the first gain in a year.
  • US retail sales fell for the second month in December.

Continue reading

The US stock market has shown signs of stabilization, trading moderately above its recent low. This recovery brings hope, suggesting the worst may be behind us. However, analyzing various metrics suggests a cautious approach. Until there’s stronger evidence to indicate that this rebound signifies a long-term recovery, remaining defensive is advisable.

Continue reading

Key updates include:

Continue reading

While it may be premature to draw definitive conclusions, early indicators from January show a widespread rally across multiple equity factors. This upsurge is particularly driven by high beta shares, as revealed through various ETF proxies.

Continue reading

In other news:

Continue reading

All major asset classes experienced gains last week, providing welcome relief after widespread losses in 2022, based on ETF proxies through the close on January 13.

Continue reading

In the latest updates:

  • Treasury Secretary Yellen indicates that the US will reach its debt limit within days.
  • China’s reopening may provide a boost to the global economy.
  • Secretary Yellen will convene with the Chinese vice premier this week.
  • Heightened recession risks persist in the US, according to a Wall Street Journal survey despite slight easing of price pressures.
  • Upcoming earnings are projected to take center stage in stock market movements over the coming weeks.
  • A mild winter lessens the impact of Russia’s energy tactics on Europe.
  • The US Treasury market yields have decreased this year, contrasting with trends from last year.
  • The head of India’s central bank has called for a blanket ban on cryptocurrency as reported.
  • The wealthiest 1% accumulate around two-thirds of the new wealth generated over the last two years.
  • US Consumer Sentiment Index rebounded in January, reaching a nine-month high.

Continue reading

For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug
Nathan Vardi
Review via Scientific American
“Finding new therapies that specifically target cancer cells while leaving healthy ones unharmed has become the ultimate goal in cancer drug research,” states Nathan Vardi, a managing editor at MarketWatch and former editor at Forbes. “For Blood and Money” follows the journey of one type of treatment (targeted small-molecule drugs designed for blood cancers) that sees two biotech firms racing to market, driven by a quest for immense profit. The narrative involves various characters, from determined scientists to ambitious entrepreneurs, and the powerful financiers maneuvering for the next billion-dollar breakthrough. Central to this tale are the patients, yearning for solutions and time.

Continue reading

Leave a Reply

您的邮箱地址不会被公开。 必填项已用 * 标注

You May Also Like